These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 6651138)

  • 21. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of low-dose intranasal scopolamine for motion sickness.
    Simmons RG; Phillips JB; Lojewski RA; Wang Z; Boyd JL; Putcha L
    Aviat Space Environ Med; 2010 Apr; 81(4):405-12. PubMed ID: 20377145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transdermal scopolamine use in the control of narcotic-induced nausea.
    Ferris FD; Kerr IG; Sone M; Marcuzzi M
    J Pain Symptom Manage; 1991 Aug; 6(6):389-93. PubMed ID: 1880439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence of acute angle-closure glaucoma in Dalmatia, southern Croatia.
    Bojić L; Mandić Z; Ivanisević M; Bucan K; Kovacević S; Gverović A; Miletić-Jurić A
    Croat Med J; 2004 Jun; 45(3):279-82. PubMed ID: 15185417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theory of antimotion sickness drug mechanisms.
    Wood CD; Graybiel A
    Aerosp Med; 1972 Mar; 43(3):249-52. PubMed ID: 4402925
    [No Abstract]   [Full Text] [Related]  

  • 26. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors.
    Gil A; Nachum Z; Dachir S; Chapman S; Levy A; Shupak A; Adir Y; Tal D
    Aviat Space Environ Med; 2005 Aug; 76(8):766-70. PubMed ID: 16110693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transdermally administered scopolamine.
    Paasuke RT
    CMAJ; 1985 Nov; 133(10):956. PubMed ID: 4063911
    [No Abstract]   [Full Text] [Related]  

  • 28. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delayed hypersensitivity to scopolamine delivered by a transdermal device.
    Trozak DJ
    J Am Acad Dermatol; 1985 Aug; 13(2 Pt 1):247-51. PubMed ID: 2931457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical manifestations of transdermal scopolamine addiction.
    Luetje CM; Wooten J
    Ear Nose Throat J; 1996 Apr; 75(4):210-4. PubMed ID: 8935644
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
    Patel PN; Ezzo DC
    Am J Health Syst Pharm; 2009 Nov; 66(22):2024-6. PubMed ID: 19890085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled topical delivery of drugs for systemic action.
    Shaw JE; Chandrasekaran SK
    Drug Metab Rev; 1978; 8(2):223-33. PubMed ID: 363384
    [No Abstract]   [Full Text] [Related]  

  • 33. Visual acuity and acute angle-closure glaucoma in Split-Dalmatia County.
    Kljajić Z; Bojić L
    Acta Clin Croat; 2008 Sep; 47(3):137-40. PubMed ID: 19175061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transdermal scopolamine use for post-rhytidectomy sialocele.
    Lapid O; Kreiger Y; Sagi A
    Aesthetic Plast Surg; 2004; 28(1):24-8. PubMed ID: 15116278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo.
    Klöcker N; Hanschke W; Toussaint S; Verse T
    Eur J Pharm Sci; 2001 May; 13(2):227-32. PubMed ID: 11297908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Scopolamine: new preparations. Reference treatment for death rattle.
    Prescrire Int; 2001 Aug; 10(54):99-101. PubMed ID: 11718188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Acute closure-angle glaucoma after treatment with ipratropium bromide and salbutamol aerosols].
    De Saint Jean M; Bourcier T; Borderie V; Moldovan M; Touzeau O; Laroche L
    J Fr Ophtalmol; 2000 Jun; 23(6):603-5. PubMed ID: 10880928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scopolamine bioavailability in combined oral and transdermal delivery.
    Nachum Z; Shahal B; Shupak A; Spitzer O; Gonen A; Beiran I; Lavon H; Eynan M; Dachir S; Levy A
    J Pharmacol Exp Ther; 2001 Jan; 296(1):121-3. PubMed ID: 11123371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Motion sickness].
    Naess K
    Tidsskr Nor Laegeforen; 1971 Aug; 91(24):1764-5. PubMed ID: 5111147
    [No Abstract]   [Full Text] [Related]  

  • 40. Human centrifuge studies on the relative effectiveness of some antimotion sickness drugs.
    Wood CD; Graybiel A; McDonough R
    Aerosp Med; 1966 Feb; 37(2):187-90. PubMed ID: 5906041
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.